• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Friday, January 27, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Bioengineering

Bioengineered cytomegalovirus protects monkeys from HIV equivalent

Bioengineer by Bioengineer
May 27, 2013
in Bioengineering
Reading Time: 2 mins read
1
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys to HIV in humans.The research team, led by Scott G. Hansen of the Oregon National Primate Research Center and the Vaccine and Gene Therapy Institute, earlier (2011) reported on their research in modified rhesus cytomegalovirus (CMV) strains. These strains belong to a family of viruses that has evolved alongside their mammalian hosts and which affect the T cell immune response. That study showed how the genetically engineered virus expressed simian immunodeficiency virus (SIV) proteins called RhCMV vectors.

aids

These vectors then allowed rhesus macaques (Macaca mulatta) vaccinated with the RhCMV to control SIV infection by modifying the T cell responses. The team reported that half of the rhesus macaques they vaccinated with the RhCMV/SIV vector were able to control SIV infection when challenged with a highly pathogenic strain.

In the current study, the team describes their latest findings, which are that a certain modified strain of CMV (68-1 RhCMV) can provoke some immune response cells (CD8+ type T cells) to respond to more antigens than they usually do and produce a much more robust response. Immunodeficiency viruses are usually able to escape the normal responses of CD8+ T cells.

T cells, or T lymphocytes, represent a type of white blood cell that matures in the thymus and plays an important role in the immune system. T cells express either CD8 or CD4 glycoproteins on their surface. Those expressing CD4 glycoprotein are known as T helper cells, since they assist other blood cells involved in the immune response, while those expressing CD8 are known as cytotoxic T cells, since they destroy infected and tumorous cells.

T cells detect a small fraction of peptides derived from pathogens that are transported to the surface of cells by class I and II major histocompatibility complex (MHC) molecules. The CD4+ T helper cells recognize antigens transported by MHC-II, while the CD8+ cytotoxic T cells recognize antigens associated with MHC-I.

When 68-1 RhCMV is present, CD8+ T cells can detect SIV epitropes, which are fragments of antigenic proteins they normally miss. They can also respond to antigens transported by MHC-II, which are normally responded to only by CD4+ T cells.

The results show that CMV can be genetically engineered to affect the body’s arsenal of CD8+ T cells so that they can recognize and mount an effective response against a wider range of peptides, and hence SIV epitopes.

The authors say their results may lead to advances in treatment of HIV in humans. The paper is published in today’s edition of the journal Science.

Tags: Bioengineeredcytomegalovirus
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Why is the first Turkish bioengineering promotion website, Biyomuhendislik.com, so important?

October 28, 2022
blank

Robo-fish

September 19, 2016

Mice born from ‘tricked’ eggs

September 17, 2016

UCLA researchers use stem cells to grow 3-D lung-in-a-dish

September 16, 2016
Please login to join discussion

POPULAR NEWS

  • Jean du Terrail, Senior Machine Learning Scientist at Owkin

    Nature Medicine publishes breakthrough Owkin research on the first ever use of federated learning to train deep learning models on multiple hospitals’ histopathology data

    63 shares
    Share 25 Tweet 16
  • First made-in-Singapore antibody-drug conjugate (ADC) approved to enter clinical trials

    57 shares
    Share 23 Tweet 14
  • Metal-free batteries raise hope for more sustainable and economical grids

    41 shares
    Share 16 Tweet 10
  • One-pot reaction creates versatile building block for bioactive molecules

    37 shares
    Share 15 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

KIMM develops the world’s first electrode design for lithium-ion battery that improves smartphone·laptop battery performance

Outlook for the blue economy

Transcendental Meditation effective in reducing burnout and depression symptoms in physicians

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 42 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In